Enclomiphene: the evidence for restoring testosterone without replacing it

Most testosterone therapy works by replacement: you add testosterone from outside, and the body, sensing it has plenty, dials down its own production. Enclomiphene is built on the opposite idea. It is an oral drug studied to make a man’s testes produce more of his own testosterone — a strategy its advocates summarize as “restoration, not replacement.” The human evidence for that claim is real and randomized. The catch is that the drug was never approved for it.

What it is

Enclomiphene is the trans-isomer of clomiphene citrate — the active half of a decades-old fertility drug.^[7] Clomiphene is a selective estrogen receptor modulator (SERM): it blocks estrogen’s signal at certain receptors. Clomiphene as sold is a mix of two isomers (enclomiphene and zuclomiphene) with opposing properties; enclomiphene is the trans-isomer that drives the rise in gonadotropins, and isolating it was the developer’s rationale for a cleaner drug.^[7]

Restoration, not replacement — the mechanism

Testosterone production is governed by the hypothalamic-pituitary-gonadal (HPG) axis, a feedback loop in which estrogen (made from testosterone) signals the brain to slow down. By blocking that estrogen brake at the hypothalamus, enclomiphene lets the pituitary release more luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which in turn tell the testes to make more testosterone and to keep producing sperm.^[8] This is the structural difference from testosterone replacement: external testosterone suppresses LH and FSH and shuts down sperm production, whereas enclomiphene raises them.^[1] It is conceptually closer to the upstream hormonal levers explored with kisspeptin than to a testosterone patch.

What the trials actually show

The earliest randomized signal came from a Phase IIB trial in men with secondary hypogonadism (n=12). After stopping testosterone gel, their baseline total testosterone sat at 165±66 pg/dL. Six months later it had climbed to 525±256 pg/dL on enclomiphene — statistically indistinguishable from the 545±268 pg/dL reached on testosterone gel. Crucially, only enclomiphene raised LH and FSH, and only enclomiphene preserved sperm: it increased counts in every man tested (to 75–334 ×10⁶/mL), while every man on gel stayed below 20 ×10⁶/mL.^[1]

A separate Phase II dose-finding RCT reinforced the picture: at week 6, the 25 mg enclomiphene dose produced a total testosterone of 604±160 ng/dL versus 500±278 ng/dL on transdermal testosterone — a difference that was not statistically significant (p=0.23). Again, enclomiphene pushed LH and FSH above the normal range, while transdermal testosterone suppressed LH.^[2]A further Phase II RCT found enclomiphene raised total testosterone, estradiol and LH in a pattern similar to gel, with FSH and LH increased and sperm counts conserved.^[3]

The headline evidence is a pair of parallel Phase III randomized trials run against AndroGel over 16 weeks. Total testosterone rose in all groups — but FSH and LH increased with enclomiphene and decreased with the gel, and where the gel arm showed a “marked reduction in spermatogenesis,” enclomiphene maintained sperm concentration in the normal range.^[4] That is the central finding of the whole program: comparable testosterone, opposite fertility outcomes.

Versus testosterone replacement: the fertility difference

For a man who wants normal testosterone but also wants to preserve fertility, this is the entire argument. Standard testosterone replacement reliably suppresses the HPG axis and can drive sperm counts toward zero; the Phase III trials showed enclomiphene reaching similar testosterone while keeping sperm concentration in the normal range.^[4] A drug-class review frames it the same way: enclomiphene raises testosterone through LH and FSH “without negatively impacting semen parameters.”^[8] This is why it is discussed for younger hypogonadal men who have not finished having children — a group for whom conventional TRT is a poor fit.

Versus clomiphene

Because enclomiphene is the isolated active isomer of clomiphene, the natural question is whether it beats the older, cheaper mixture. A 2023 meta-analysis (7 studies, 292 men) found enclomiphene increased testosterone by +7.50 nmol/L (95% CI 6.52–8.48) and clomiphene by +11.56 nmol/L — so clomiphene raised testosterone more on average, not less.^[5] A 2024 retrospective comparison (n=66) found enclomiphene’s median testosterone rise (+166 ng/dL) was numerically larger than clomiphene’s (+98 ng/dL) but not statistically different (P=0.20). Where enclomiphene looked cleaner was estradiol — a smaller change (−5.92 vs +17.50 pg/mL, P=0.001) — and tolerability, with fewer adverse events (odds ratio 0.18, 95% CI 0.07–0.44).^[6] So the case for enclomiphene over clomiphene rests more on a cleaner side-effect and estrogen profile than on raw testosterone gains.

The catch: never FDA-approved, and compounded

Here is what the marketing tends to skip. Despite this evidence, enclomiphene was developed as Androxal by Repros Therapeutics and its New Drug Application was not approved; the drug-profile review literature explicitly discusses the difficulties the program had with FDA approval.^[7] Clomiphene itself is FDA-approved only for ovarian dysfunction in women, which makes any use in men inherently off-label.^[8] In practice, that means enclomiphene reaches men today mostly through compounding pharmacies — an unregulated supply chain where dose, purity and identity are not guaranteed.

What we still don’t know

The evidence has real limits worth stating plainly. The foundational Phase II and III trials were run by the drug’s developer (Repros Therapeutics, with Wiehle and colleagues), and some later authors have pharmaceutical ties — a conflict-of-interest pattern that should temper how cleanly we read the results.^[1][2] The trials were also small and short: weeks to a few months, with no long-term data on bone density, cardiovascular events, or mortality — exactly the outcomes that matter most when a therapy might be taken for years. The same caution applies to other hormone-axis peptides we cover, from tesamorelin to PT-141; you can see where each sits in our peptide evidence matrix.

The honest bottom line

Enclomiphene is one of the better-evidenced ideas in this space: multiple randomized trials, including two Phase III RCTs, show it restoring a man’s own testosterone to normal while preserving the fertility that testosterone replacement sacrifices. That is a genuine, mechanistically coherent advantage. But the FDA did not approve it for male use, the supportive trials were small, short and sponsor-run, and the product men actually take is compounded and unregulated. The fairest summary is that enclomiphene is a promising, off-label restoration strategy with solid short-term data and an important unanswered question about the long run — not a settled, approved therapy.

Going deeper: how it stacks up against testosterone replacement and clomid, what the trials used for dosage, the side-effect profile, and how to get it legitimately.